ArticleNeurochemical research2012
Total antioxidant status correlates with cognitive impairment in patients with recurrent depressive disorder.
Article in Neurochemical research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 35 citations in OpenAlex.
- Melatonin's neuroprotective role in mitochondria and its potential as a biomarker in aging, cognition and psychiatric disorders.Translational psychiatry · 2021Review
- Article
- Interleukin 1 level, cognitive performance, and severity of depressive symptoms in patients treated with systemic anticancer therapy: a prospective study.Croatian medical journal · 2019Article
- Article
- Serum KIBRA mRNA and Protein Expression and Cognitive Functions in Depression.Medical science monitor : international medical journal of experimental and clinical research · 2016Article
- The role of interleukin genes in the course of depression.Open medicine (Warsaw, Poland) · 2016Article
- Impact of pharmacological and psychological treatment methods of depressive and anxiety disorders on cognitive functioning.Journal of neural transmission (Vienna, Austria : 1996) · 2015Review
- Mechanisms underlying neurocognitive dysfunctions in recurrent major depression.Medical science monitor : international medical journal of experimental and clinical research · 2015Review
- Serum Levels of ApoA1 and ApoA2 Are Associated with Cognitive Status in Older Men.BioMed research international · 2015Article
- ASMT gene expression correlates with cognitive impairment in patients with recurrent depressive disorder.Medical science monitor : international medical journal of experimental and clinical research · 2014Article
- Impact of oxidative/nitrosative stress and inflammation on cognitive functions in patients with recurrent depressive disorders.Medical science monitor : international medical journal of experimental and clinical research · 2014Article
- Antioxidant status and APOE genotype as susceptibility factors for neurodegeneration in Alzheimer's disease and vascular dementia.Rejuvenation research · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledDepressive disorder is a multifactorial diseases, that one of the typical feature are cognitive impairments. The aim of this study was to determine the total antioxidant status (TAS) in patients with recurrent depressive disorder (rDD) and to define relationship between plasma levels of TAS and the cognitive performance. DESIGN AND
methodsthe study comprised 74 subjects: patients with rDD (n = 45) and healthy subjects (n = 29). Cognitive function assessment was based on: Trail Making Test, The Stroop Test, Verbal Fluency Test and Auditory Verbal Learning Test. Statistically significant differences were found in the intensity of depression symptoms, measured by the Hamilton Depression Rating Scale (HDRS) on therapy onset versus the examination results after 8 weeks of treatment (p < 0.001). The level of TAS was substantially higher in patients with rDD (p = 0.01). For rDD patients, elevated TAS levels were associated with worse cognitive test performance. The higher was the concentration of plasma TAS, the greater was the severity of depressive symptoms measured by HDRS before and after pharmacotherapy. (1) Higher concentration of plasma TAS in rDD patients is associated with the severity of depressive symptoms. (2) Elevated levels of plasma TAS are related to impairment of short-term declarative memory, long-term declarative-memory, verbal fluency and working memory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.